939
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis

, , , , , , , & show all
Pages 371-381 | Received 29 Sep 2016, Accepted 05 Dec 2016, Published online: 12 Jan 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Weixian Hu, Chengbin Zheng, Renjie Li, Xingyu Feng, Guoliang Zheng, Zhichao Zheng, Wenjun Xiong, Guosheng Lin, Yongjian Zhou, Wei Wang, Yan Zhao & Yong Li. (2020) Retroperitoneal Extragastrointestinal Stromal Tumors Have a Poor Survival Outcome: A Multicenter Observational Study. Cancer Management and Research 12, pages 10491-10504.
Read now
Monia Marchetti. (2017) Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 469-480.
Read now

Articles from other publishers (2)

Rumjhum Agrawal, Joao Vieira, Jacqueline Ryan, Harish Negi, Tanvi Rajput, Regina Corbin & Ricardo Viana. (2022) A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia. PharmacoEconomics 40:12, pages 1159-1186.
Crossref
Vikalp Kumar Maheshwari, Cassandra Slader, Nidhi Dani, Christina Gkitzia, Quan Yuan, Tengbin Xiong, Yu Liu & Ricardo Viana. (2021) Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China. PLOS ONE 16:10, pages e0259076.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.